ALX Oncology Holdings Inc. (ALXO)
NASDAQ: ALXO · Real-Time Price · USD
1.155
+0.005 (0.43%)
Nov 6, 2026, 4:00 PM EST - Market closed
ALX Oncology Holdings Employees
ALX Oncology Holdings had 48 employees as of June 30, 2026. The number of employees decreased by 1 or 2.04% compared to the same quarter last year. That makes ALX Oncology Holdings the 35,144th largest employer in the world and 4,701st in the United States.
Employees
48
Change (1Y)
-1
Growth (1Y)
-2.04%
Revenue / Employee
n/a
Profits / Employee
-$1,685,208
Market Cap
159.71M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 48 | -1 | -2.04% |
| Mar 31, 2026 | 43 | -22 | -33.85% |
| Dec 31, 2025 | 43 | -37 | -46.25% |
| Sep 30, 2025 | 44 | -45 | -50.56% |
| Jun 30, 2025 | 49 | -32 | -39.51% |
| Mar 31, 2025 | 65 | -9 | -12.16% |
| Dec 31, 2024 | 80 | 8 | 11.11% |
| Sep 30, 2024 | 89 | 18 | 25.35% |
| Jun 30, 2024 | 81 | 9 | 12.50% |
| Mar 31, 2024 | 74 | 9 | 13.85% |
| Dec 31, 2023 | 72 | 14 | 24.14% |
| Sep 30, 2023 | 71 | 16 | 29.09% |
| Jun 30, 2023 | 72 | 20 | 38.46% |
| Mar 31, 2023 | 65 | 21 | 47.73% |
| Dec 31, 2022 | 58 | 15 | 34.88% |
| Sep 30, 2022 | 55 | 23 | 71.88% |
| Jun 30, 2022 | 52 | 23 | 79.31% |
| Mar 31, 2022 | 44 | 20 | 83.33% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Entrada Therapeutics | 152 |
| Sutro Biopharma | 128 |
| MediWound | 121 |
| Inovio Pharmaceuticals | 112 |
| Zentalis Pharmaceuticals | 106 |
| Sionna Therapeutics | 59 |
| PepGen | 57 |
| Whitehawk Therapeutics | 32 |
ALXO News
- 5 weeks ago - ALX Oncology announces publication of data from ASPEN-06 Phase 2 trial - TheFly
- 5 weeks ago - ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer - GlobeNewsWire
- 7 weeks ago - ALX Oncology Holdings Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 1 month ago - ALX Oncology Holdings Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 1 month ago - ALX Oncology Holdings Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 2 months ago - ALX Oncology to Present at Upcoming Investor Conferences in September - GlobeNewsWire
- 3 months ago - ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - ALX Oncology Holdings Earnings release: Q2 2026 - Filings